NanoVibronix Applies For Inclusion Of UroShield Products In NHS Prescription Services' Drug Tariff
Portfolio Pulse from Happy Mohamed
NanoVibronix, Inc. (NASDAQ:NAOV) has applied for inclusion of its UroShield products in the National Health Service (NHS) Prescription Services' Drug Tariff in the UK. If approved, the listing would enable reimbursement and increased distribution for NHS patients. The company's CEO, Brian Murphy, believes that the inclusion would allow UroShield technology to be reimbursed and gain broader distribution through pharmacies.
August 28, 2023 | 12:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
NanoVibronix's application for inclusion of its UroShield products in the NHS Prescription Services' Drug Tariff could lead to increased distribution and reimbursement for NHS patients. This could potentially boost the company's revenues and market presence.
If NanoVibronix's application is approved, it would mean that the NHS would cover the cost of UroShield devices, making them more accessible to patients. This could lead to increased sales and revenues for NanoVibronix. Furthermore, the broader distribution through pharmacies could enhance the company's market presence in the UK.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100